Provides laboratory medicine and pathology testing services. Offers radiology services including MRI, CT scans, and X-rays. Now — the numbers.
This is an established company with proven profits.
No real growth (4% a year).
The gap is $3.7B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 15.5× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
An investor who bought at the very peak is down 60% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It pays out $0.77 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back.
Getting in and out without moving the price could prove difficult.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.